Contents lists available at ScienceDirect

Experimental and Molecular Pathology

journal homepage: www.elsevier.com/locate/yexmp

Q2 Role of microRNA-34 family in cancer with particular reference to cancer angiogenesis

Q3 Hamidreza Maroof, Ali Salajegheh, Alfred King-Yin Lam *

4 Cancer Molecular Pathology, School of Medicine and Griffith Health Institute, Griffith University, Gold Coast, Queensland, Australia

ARTICLE INFO

Article history:

Received 31 July 2014

Accepted 1 August 2014

Available online xxxx

Keywords:

miRNA-34

Cancer

Angiogenesis

ABSTRACT

MicroRNA-34 is involved in pathogenesis in cancer by targeting different tumor-related genes. It could be a 14 biomarker for predicting the prognosis of patients with cancer. In addition, miR-34 is involved in the tumor 15 angiogenesis. Understanding the mechanism of the miR-34 in cancer and tumor angiogenesis will open horizons 16 for development of anti-cancer and anti-angiogenesis drugs. 17

© 2014 Published by Elsevier Inc.

Contents

1. Introduction	0
2. miR-34 family	0
3. Cancer and miR-34	0
4. Angiogenesis and miR-34	0
5. Conclusion	0
6. Uncited references	0
Acknowledgments	0
References	0

1. Introduction

Q4 Since the discovery of miRNA in *Caenorhabditis elegans* (Lau et al., 2001; Lee and Ambros, 2001), many researchers have focused their attention into elucidating the aspects of miRNA biology and function. Classed as the new generation of epigenetic gene regulators (Benetti et al., 2008; Cai et al., 2009; Szulwach et al., 2010), miRNAs are 20–25 nucleotides non-coding RNAs which is estimated that about 30% of gene expression is regulated using miRNA (Winter et al., 2009). Their main goal is repression of gene expression. After transcription by RNA polymerase II, the pri-miRNA is processed with Drosha (RNase III) and subsequently in the cytoplasm with Dicer to yield a double strand RNA. This form is then cleaved into a single strand RNA as a mature

miRNA which is then incorporated into miRNA–protein (miRNP) 46 complex. The miRNA in the miRNP complex identifies the seed sequence in the 3' untranslated region of the target mRNA and then either Q6 suppresses the translation or degrades the mRNA. Both processes result in downregulated expression of protein (Bartel and Chen, 2004; Huang et al., 2011; Krol et al., 2010). Additionally, it has been shown that they are able to directly bind proteins (Hafner et al., 2010; van Kouwenhove et al., 2011). Therefore, on a hypothetical assumption and considering the account of mRNA genes, their varied expression patterns and consequently the vast potential of miRNA targets suggest that miRNAs are likely to be involved in an extended spectrum of cellular processes. More than 60% of human protein-coding genes are conserved targets of miRNA (Siomi and Siomi, 2010). The functional roles of miRNAs have been reported in many biological events including developmental timing (Ambros, 2011; Li et al., 2011), signal transduction (Inui et al., 2010) and tissue differentiation (Chen and Hu, 2012; Ge and Chen, 2011; Huang et al., 2011). Thus, miRNAs play variety of functions in

* Corresponding author at: Head of Pathology, Griffith Medical School, Gold Coast Campus, Gold Coast, QLD 4222, Australia.
E-mail address: a.lam@griffith.edu.au (A.K.-Y. Lam).

the biology of human. Also, it has been shown that an alteration in miRNA expression is related to various diseases including cancer (Ebrahimi et al., 2014; Gopalan et al., 2014; Sayed and Abdellatif, 2011).

2. miR-34 family

The miR-34 microRNA precursor family was computationally discovered and later verified experimentally. The two distinct precursors are processed into three mature miRNAs: miR-34a, miR-b and miR-c. The mature miR-34a is a part of the p53 tumor suppressor network (Concepcion et al., 2012; Liu et al., 2012); therefore, it is hypothesized that miR-34 dysregulation is involved in the development of some cancers (Gopalan et al., 2014). This family is transcribed from two different sets of genes located on chromosomes 1 and 11. Higher expression of miR-34a was detected in brain and higher expression of miR-34b and miR-34c was noted in lungs (Lagos-Quintana et al., 2002). The presence of miR-34 products has also been confirmed in embryonic stem cells (Houbaviy et al., 2003). Their promoter region has p53 binding site therefore they are induced by p53 and thus involved in cell proliferation, survival, apoptosis (Yamakuchi et al., 2008), migration, invasion (Siemens et al., 2011) and angiogenesis (Chang et al., 2007; Yamakuchi and Lowenstein, 2009). Many controlling genes are regulated through the actions of this family. For example, ectopic expression of this family of miRNAs results in an increase in factors involved in cell cycle regulation and DNA damage response and suppression of cell cycle promoting genes (Wan et al., 2011). Each member of this family is able to induce similar gene expression and repression (Hermeking, 2010). Given their similar structure, such pattern was predictable. On the other hand, it seems that each member has an extra affinity to a specific mRNA, which is the result of perfect complementary sequences. For instance, miR34b and miR34c have higher tendency to suppress c-myc.

miR-34a, miR-34b and miR-34c are responsible for cell-cycle arrest in the G1 phase. In addition, miR-34b/c inhibited proliferation and colony formation in soft agar. Interestingly, the introduction of miR-34a, miR-34b and miR-34c into primary human diploid fibroblasts induced cellular senescence. Microarray analyses after ectopic introduction of different members of the miR-34 family into various cell lines revealed hundreds of putative, downregulated miR-34 targets. Cyclin D1, cyclin E2, cyclin-dependent kinases 4 and 6, mitogen-activated protein kinase 1 (MEK1), R-Ras, platelet-derived growth factor receptor A (PDGFR α), and hepatocyte growth factor receptor are among the direct targets that have been experimentally validated (Li et al., 2009). As a member of p53 pathway, additionally miR34 regulates the genes involved in apoptosis (Bommer et al., 2007; Chang et al., 2007). Survivin and BCL2 (B-cell lymphoma 2) are anti-apoptotic proteins regulated by miR-34a. On the other hand, miR-34 targets the regulatory molecules of p53 which include SIRT1 (silent mating type information regulation 2 homolog 1) and YY1 (yin yang 1). SIRT1 is a NAD⁺ dependent class III histone deacetylase that protects cells against oxidative and genotoxic stress (Brooks and Gu, 2009). This downregulation creates a positive feedback loop for p53, enhancing its half-life and function. As p53 increases miR-34a transcription, increased amounts of p53 eventually lead to higher levels of miR-34a (Bommer et al., 2007; Yamakuchi et al., 2008).

3. Cancer and miR-34

Many miRNAs are deregulated in cancers via various mechanisms (Sevignani et al., 2007). Genomic abnormalities such as deletion (Sevignani et al., 2007), amplification (Hayashita et al., 2005; Rinaldi et al., 2007; Tagawa et al., 2007), and translocation (Dorsett et al., 2008) are common in tumorigenesis. miR-15a and miR-16-1 are examples which are clustered at chromosome 13q14, a frequently deleted region in B cell chronic lymphocytic leukemia and other cancers (Calin et al., 2002). Epigenetic factors are heritable transcriptional silencing which can also influence miRNA expression. CpG island

hypermethylation and histone modification in promoter regions result in silencing of tumor-suppressor genes. Microarray analyses have indicated some miRNAs that are repressed by CpG hypermethylation in cancers relative to normal tissue (Lehmann et al., 2008). For instance, miR-9-1 in breast cancer and miR-34a in hematological malignancies are among the hypermethylated (Chim et al., 2010). Transcriptional and post-transcriptional regulations can also affect the expression of miRNAs. pri-miRNAs are induced by transcription factors, and many of which are oncogenes or tumor suppressors. Many miRNA–transcription factor relationships have been discovered in cancers such as in p53, c-Myc, and E2F (E2 transcription factor) (Tazawa et al., 2007).

mi-RNA processing and stability are also important factors that determine mi-RNA expression level. In addition, the expression levels of mi-RNA processing machinery, Dicer or Drosha, are altered in a number of cancers, likely due to the copy number gain (Blenkiron et al., 2007; Chiosea et al., 2007; Karube et al., 2005; Muralidhar et al., 2007).

Known to regulate cell cycle, apoptosis, and differentiation, miR-34 is one of the best-characterized tumor suppressor miRNAs to date. It is lost or expressed at reduced levels in many cancers. miR-34 functions downstream of p53 by regulating genes to induce cell cycle arrest, cellular senescence and apoptosis and re-introduction of miR-34 mimics growth inhibition in vitro and in vivo (Ji et al., 2008). Although p53 has direct activating effects, studies have shown that miR-34b is hypermethylated and therefore silenced in many types of cancer including colorectal carcinoma (Toyota et al., 2008), gastric carcinoma (Ji et al., 2008), mesothelioma (Kubo et al., 2011), breast carcinoma (Vogt et al., 2011), ovarian carcinoma (Corney et al., 2010; Segura et al., 2009), renal cell carcinoma, urothelial carcinoma (Catto et al., 2011), pancreatic carcinoma (Chang et al., 2007), prostatic carcinoma (Fujita et al., 2008), lung carcinoma (Bommer et al., 2007; Lodygin et al., 2008; Wiggins et al., 2010) and melanoma (Lodygin et al., 2008; Segura et al., 2009). This phenomenon is present despite the presence of wild type p53 (Christoffersen et al., 2010). In this regard, treatment with demethylating agents was able to activate its expression and inhibit malignant growth in vitro (Kong et al., 2012; Nalls et al., 2011; Roy et al., 2012). Thus, genetic and epigenetic mechanisms contribute to a loss of miR-34 expression.

The side effects and chemo-resistance tendencies of conventional chemotherapies are giving way to more selective non-toxic treatments, which target a defined specific tumor related gene (Tsao et al., 2005; Welch and Moore, 2007). As modulators of gene expression and controllers of many cellular pathways, miRNAs play important role in the regulation of tumor suppression. Some of important miRNAs are let-7, miR-34 and miR-200 (Kasinski and Slack, 2011).

miRNA replacement treatment has resulted in anti-proliferative, pro-apoptotic, and death in cancer cell (Bader et al., 2010). miR-34 is a well-known tumor suppressor, and extensive aberrant expression profile has been observed in many cancers which reintroduction of miR-34a inhibits cancer cell growth and shows its important role in tumorigenesis. Additionally, studies have shown that an important ability of miR-34 is inhibition of cancer stem cells. CD44 or CD133 positive prostate and breast cancer cells express lower levels of miR-34a. Also, ectopic expression of miR-34 hampers sphere formation in soft agar and tumorigenicity in vivo (de Antonellis et al., 2011; Ji et al., 2009; Liu et al., 2011a; Yu et al., 2012).

This impact can be attributed to the inhibitory effects miR34 has on pluripotency genes *NANOG* (*Nanog homeobox*), *SOX2* (*SRY (sex determining region Y)-box 2*), and *MYCN* (*v-myc myelocytomatosis viral related oncogene, neuroblastoma derived [avian]*) (Choi et al., 2011; de Antonellis et al., 2011). Other pathways regulated by miR34 include Wnt signaling (Cha et al., 2012; Siemens et al., 2011), AKT (protein kinase B) pathway (Lal et al., 2011) and notch (Fujita et al., 2008) which regulate growth, epithelial–mesenchymal transition (EMT) and metastasis.

Given that more than 50% of all human cancers show defects in the p53 pathway, miR-34 replacement therapy is likely to become a

powerful therapeutic approach. The ability of miR-34 to influence several pathways may be synergistically beneficial when combined with conventional therapies. As experiments have shown, miR-34a alleviates chemo-resistance in various cancer cell models (Fujita et al., 2008). This attenuation has been partly attributed to the modulatory role of miR-34 on HuR, Bcl-2, Sirt1 MAGE-A and p53 expressions (Kojima et al., 2010; Weeraratne et al., 2011). As cell models have shown the efficacy of miR-34 treatment, there are few animal studies which have shown that vector-based delivery of miR-34 has therapeutic potential (Hu et al., 2010; Kato et al., 2009; Kota et al., 2009; Kumar et al., 2008; Wiggins et al., 2010; Yan et al., 2011). However, the ultimate therapeutic benefits of miR-34 in vivo depend largely on the delivery system. As promising the animals are, development of a safe clinically relevant system needs further enhancement to achieve the standards of clinical trial drugs. In this regard, micro-RNA therapeutics initiated a screening process on various delivery systems with the aim of finding the most suitable system. The criteria included were (a) efficacy in mouse models of cancer, (b) miRNA bio-distribution, and (c) initial safety.

miRNAs have been the focus of many studies in cancer prognosis and diagnosis (Cho, 2010). Studies have shown that miRNAs are secreted as exosomes and can be used as early biomarkers in body fluids for disease diagnosis, prognosis, and response to treatment. As one of the tumorigenesis-related miRNAs, miR-34 has been studied extensively in cancers. miR-34a expression has been linked to metastases in prostate (Watahiki et al., 2011), breast (Javeri et al., 2013), and colorectal (Siemens et al., 2013) cancers suggesting that it could be a potential biomarker. Additionally, patient with non-small cell lung carcinoma that has undergone resecting surgery was noted to have a longer survival if the cancer shows up-regulated miR-34a expression (Mudduluru et al., 2011). In a study by Koufaris et al., it has been shown that hepatocellular carcinoma cells exposed to DNA damage or oxidative stress blocked abnormal cell proliferation when treated with miR-34a (Koufaris et al., 2012). This suggests that miR-34a can be utilized in the detection of hepatocellular carcinoma. Furthermore, it has been reported that decreased expression of miR-34a is linked with pathogenesis, adverse outcome (Koufaris et al., 2012) and poorer overall survival (Hu et al., 2013).

4. Angiogenesis and miR-34

Due to their high metabolic rate, cancer cells are dependent on extra amount of blood supply. Angiogenesis is one of the hallmarks of cancer. Angiogenesis is a normal physiological processes utilized in situations which higher levels of nutrients are needed, for example in wound healing and developing embryo (Breier, 2000). However, the growing tumor cells take advantage of this process. Several processes are involved in formation of new microvasculature. Detachment of pericytes, extra cellular matrix degradation and reformation by stromal cells and guided migration and proliferation of endothelial cells by molecular mediators, sequentially govern the formation of new blood vessels (Carmeliet, 2005; Flamme et al., 1997; Otrock et al., 2007).

There are many factors that regulate cancer angiogenesis. The most important is vascular endothelial growth factor (VEGF). VEGF was noted by regulating the pathogenesis and predicting the prognosis of human cancers (Ferrara et al., 2003; Harhaj et al., 2006; Salajegheh et al., 2011, 2013; Weekes et al., 2010; Yu et al., 2008a,b). It is the main target for treatment in human cancers. Other angiogenic factors include endothelins and their receptors (Irani et al., 2014a,b), angiopoietins and their respective Tie receptors (Loughna and Sato, 2001), fibroblast growth factor (Presta et al., 2005), and platelet-derived growth factor (Hellstrom et al., 1999).

Likewise, there are many studies showing the manifold impacts of mi-RNAs in the biology of endothelial cells. mi-RNAs have emerged as an important factor regulating cellular function and responses. The importance of mi-RNAs in endothelial cell function was demonstrated by the silencing of the Dicer enzyme, which resulted in the reduction of

the mature mi-RNA profile. Increased activation of the eNOS pathway (Bonauer et al., 2009), reduced endothelial proliferation, migration and cord formation was the consequence of dicer knock down (Suárez et al.). The above results show that mi-RNAs are important in the physiological function of endothelial cells.

As a network, mi-RNAs regulate the process of angiogenesis in endothelial cells, balancing the pro- and anti-angiogenic responses. Twenty seven highly expressed mi-RNAs have been identified to play role in endothelial biology, 15 of which were predicted to regulate the expression of receptors for angiogenic factors. For example, the expression of VEGFR2, endothelial nitric oxide synthesis (eNOS) (Yang et al., 2005) and interleukin-8 (IL-8) (Bhaumik et al., 2009) is shown to be regulated via mi-RNAs. Other exemplary pro-angiogenic miRNAs include mi-R130a, mi-R210, mi-R424, let-7 family, miR-27b and the miR-17-92 cluster. Also, mir-221 and mir-222 are anti-angiogenic miRNAs. The names and function of involved angio-miRs were summarized in Table 1.

A growing tumor, demands extra amount of oxygen and unlike physiological conditions, induces its own blood vessels via sprouting of existing capillaries or recruitment of circulating endothelial progenitor cells (Miles, 1999). Tumors are able to produce the above-mentioned angiogenic factors in copious amounts. It has been shown that a relatively high amount of VEGF and its receptor is expressed on tumor cells and the respective endothelial and stromal cells (Ferrara, 2002). To demonstrate the important role of VEGF, administration of anti-VEGF or anti-Flk-1 (VEGF receptor) antibodies in vivo was able to decrease tumor vessel density and inhibit tumor growth (Brekken et al., 2000). These evidences show that inhibition of VEGF activity in vivo results in reduced tumor angiogenesis and tumor growth.

On cellular level, tumor-induced vessels have abnormal structure. High amounts of VEGF along with Ang2 expression induce a rather “leaky vessel” structure with increased permeability, incomplete cellular junction and a lack of basement membrane (Manley et al., 2004). The vascular bed is sufficient to provide the tumor cells with adequate nutrient supply and the opportunity to enter the circulation and form distant metastases. In the tumor microenvironment, local oxygen concentrations regulate VEGF production. Hypoxia stimulates the binding of hypoxia-inducible factor (HIF) to the VEGF promoter, promoting VEGF gene transcription and mRNA stability (Arany et al., 2008). The pressure of hypoxic environment not only induces the production of VEGF, but also aids the selection of apoptosis resistant tumor cells. These cells are the P53 mutant-type cells and that explains the phenomenon of increased amount of cells harboring this phenotype in higher stages of cancer (Semenza, 2000, 2002).

IL-8 is another mediator which has shown angiogenic abilities. In the tumor microenvironment, IL-8 is produced from macrophages in a state of chronic inflammation (Chen et al., 2005; Koch et al., 1992). It has been shown that IL-8 is mitogenic and chemotactic for HUVECs and angiogenic in rat cornea (Waugh and Wilson, 2008). It also has the effect of increasing the expression and activity of matrix metalloproteinase 2 (MMP2) (Reis et al., 2012). Considering the important role of angiogenesis in the growth of tumor cells, inhibition of this process has been one of the major focuses in anti-cancer biology and therapeutic research (Ferrara and Kerbel, 2005; Shojaei, 2012; Sitohy et al., 2012; Welti et al., 2013). For example, bevacizumab, a FDA-approved monoclonal antibody against VEGF, has been successfully used in combination with chemotherapy agents in clinical trials (Aghajanian et al., 2014; Ferrara et al., 2004; Kopetz et al., 2010; Perren et al., 2011). Bevacizumab was able to inhibit endothelial sprouting and normalize the architecture of vessels, enhancing drug uptake of the tumor (Arjaans et al., 2013; Carmeliet and Jain, 2011; Ma et al., 2011). Since then, targeting the VEGF pathway was the focus of anti-angiogenesis developments. However, several groups described that these drugs may actually accelerate metastases formation. Therefore, other targets also need to be considered (Bagri et al., 2010).

Table 1

List of miRNAs which have role in endothelial physiology and in tumor angiogenesis.

Name	Target	Function	References
miR-126	<i>SPRED1, PIK3R2, VCAM1</i>	Maintaining vascular integrity, endothelial cell proliferation, migration, tube formation and sprouting	Wang et al. (2008)
miR-221 and miR-222	<i>p27, c-kit mRNA</i>	Regulates cell cycle progression, decreased cell migration and downregulation of endothelial nitric oxide synthase expression	Nicoli et al. (2012)
miR-17–92 cluster	<i>HIF-1 alpha, E2F1, ITGA5</i>	Endothelial cell sprouting, tube formation, pro-angiogenesis phenotype and reduce p53	Doebele et al. (2010)
miR-130a	<i>GAX, HOXA5</i>	Proliferation, migration, and tube formation	Volpe et al. (2012), Zhang et al. (2011)
miR-21 and miR-31	<i>HIF-1alpha expression, PTEN suppression</i>	Inducing matrix metalloproteinase expression	Liu et al. (2011b)
miR-320	<i>VEGFR2, IGF-1, IGF-1R</i>	Anti-angiogenesis	Wang et al. (2014), Wu et al. (2014)
let-7 family and miR-27b	<i>Tsp-1</i>	Sprout formation	Bao et al. (2013)
miR-155	<i>Angiotensin II type I receptor</i>	Anti-angiogenesis	Kong et al. (2013)
miR-210	<i>Ephrin-A3 (EFNA3), Neuronal pentraxin-1 (NPTX1)</i>	Pro-angiogenesis, tubulogenesis and VEGF induced migration of endothelial cell growth	Alaiti et al. (2012)
miR-296	<i>Hepatocyte growth factor-regulated tyrosine kinase substrate, PDGFRβ</i>	Elevated in tumor endothelial cells, tubule length and branching of endothelial cells	(Savi et al. (2014); Vaira et al. (2012))
miR-378	<i>SUFU, FUS-1b</i>	Promotes tumorigenesis and angiogenesis in vivo	Chen et al. (2012)
miR-20a and miR-20b	<i>VEGF, BCL2</i>	Induces apoptosis block cell cycle progression	Sun et al. (2013)
miR-15 and miR16			
miR-34a	<i>SIRT1, Survivin, E2F3, CDK4</i>	Endothelial senescence	Yamakuchi et al. (2008)
miR-34b	<i>CREB</i>	Restoration of cell cycle abnormality reduce anchorage-independent growth	Mazar et al. (2011)
miR-217	<i>SIRT1, FOXO3A</i>	Endothelial senescence	Zhang et al. (2013)
miR-424	<i>CHK1</i>	Migration and proliferation of endothelial cells	Ghosh et al. (2010), Nakashima et al. (2010)
miR-200c	<i>ZEB1</i>	Senescence in response to proto-oncogene tyrosine-protein kinase (ROS) and increase p53 level	Rebustini et al. (2012)
miR-9	<i>E-cadherin</i>	Increased migration and angiogenesis	Zhuang et al. (2012)

mi-RNAs can control endothelial cell function as angioregulatory switches in tumor angiogenesis. Since a single mi-RNA has the ability to regulate a variety of endothelial functions by targeting multiple mRNAs, miRNA targeted therapy could greatly influence endothelial cell behavior. In this regard, miRNAs, especially those that are involved in endothelial cell biology, have attracted attention for targeted anti-angiogenesis therapy. Of note, in anti-cancer therapies, cellular senescence has an important role.

Numerous miRNAs are engaged in the regulation of cellular senescence of endothelial cells. A study evaluated the expression of miR-34a in primary endothelial cells and demonstrated that baseline expression increases during cell senescence (Ito et al., 2010). miR-34a regulates proliferation and differentiation of many cell types. Similarly, miR-34 controls the cycle in endothelial cells. It decreases SIRT1 levels and increases acetylation of p53 (Yamakuchi et al., 2008). Mammalian SIRT1 functions as a metabolic regulator by deacetylation of histones and large numbers of proteins including protein 53 (p53), Ku70 protein, nuclear factor κβ (NF-κβ), and peroxisome proliferator activated receptor γ (Brooks and Gu, 2009). It has been shown that miR-34a expression is downregulated in highly angiogenic endothelial cells (endothelial cells overexpressing Bcl-2) as compared to normal human endothelial cells (Zhao et al., 2010).

miR-34a expression was analyzed in head and neck squamous cell carcinoma cell line and 15 cancer r samples of oral cavity, oropharynx and larynx. Bhavna and the team demonstrated that miR-34a could regulate tumor angiogenesis through down-regulation of key proteins including E2F3, SIRT1, survivin and CDK4 whereby the function of endothelial cell was directly inhibited. E2F3a and E2F3b are important family of transcriptional factors that play pivotal role in cell proliferation and differentiation and cell cycle regulation. They also studied the correlation of VEGF expression to miR-34a as the main player in angiogenesis process and demonstrated that overexpression of miR-34a down-regulated the upstream proteins of VEGF expression such as E2F3, Myc and c-met in both of head and neck squamous cell carcinoma cell line and cancer tissue

The expression of VEGF was significantly reduced in cell lines over-expressing miR-34a. In addition, the miR-34a was shown to have direct effects on the proliferation and migration of endothelial cells and tube formation was inhibited in vitro (Kumar et al., 2012).

5. Conclusion

Increased number of studies is vital to identify endothelial miRNAs and characterize their potential for anti-angiogenesis therapeutics in cancer. Investigations have shown that the altered expression of miRNAs in the endothelial cells is under VEGF-stimulation, hypoxia, or tumor signaling. However, utilization of miRNAs in therapy has the potential side effect of off target effects, which are likely due to the partial complementarity between a miRNA and target mRNA and depending on the cell type. Therefore, specific delivery strategies to the site of ongoing tumor angiogenesis are vital. Besides there can be different approaches: anti-angiogenesis miRNAs to sites of tumor which could directly 'switch off' the angiogenesis process or inhibit the activity of pro-angiogenesis miRNAs (antagomiRs).

Evaluation of the roles miRNAs play in endothelial biology and its relation in various ailments is a relatively new field of research, with high expectations for research and therapy applications. However, this field is in its first steps, and many pitfalls have to be overcome before successful miRNA targeted anti-angiogenesis therapy will reach the clinic. A better understanding of miRNA regulation in endothelial cell is essential. Moreover, a comprehensive mapped miRNA profile is necessary to identify the specific miRNAs involved in tumor angiogenesis. Hopefully, this new emerged research field will open prospect full horizons for the development of anti-angiogenesis drugs involving miRNAs.

6. Uncited references

Fleissner et al., 2010
Katoh, 2013

Acknowledgments

The authors would like to thank the staff and students in Molecular Cancer Pathology team in Griffith Health for the help in manuscript. The work is supported by funding from Griffith University.

References

- Aghajanian, C., Goff, B., Nycum, L.R., Wang, Y., Husain, A., Blank, S., 2014. Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer. *Gynecol. Oncol.*
- Alaiti, M.A., Ishikawa, M., Masuda, H., Simon, D.I., Jain, M.K., Asahara, T., et al., 2012. Up-regulation of miR-210 by vascular endothelial growth factor in ex vivo expanded CD34+ cells enhances cell-mediated angiogenesis. *J. Cell. Mol. Med.* 16, 2413–2421.
- Ambros, V., 2011. MicroRNAs and developmental timing. *Curr. Opin. Genet. Dev.* 21, 511–517.
- Arany, Z., Foo, S.-Y., Ma, Y., Ruas, J.L., Bommi-Reddy, A., Girmun, G., et al., 2008. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1 α . *Nature* 451, 1008–1012.
- Arjaans, M., Munnink, T.H.O., Oosting, S.F., van Scheltinga, A.G.T., Gietema, J.A., Garbaciak, E.T., et al., 2013. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. *Cancer Res.* 73, 3347–3355.
- Bader, A.G., Brown, D., Winkler, M., 2010. The promise of microRNA replacement therapy. *Cancer Res.* 70, 7027–7030.
- Bagri, A., Kourou-Mehr, H., Leong, K.G., Plowman, G.D., 2010. Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale. *Trends Mol. Med.* 16, 122–132.
- Bao, M.-H., Feng, X., Zhang, Y.-W., Lou, X.-Y., Cheng, Y., Zhou, H.-H., 2013. Let-7 in cardiovascular diseases, heart development and cardiovascular differentiation from stem cells. *Int. J. Mol. Sci.* 14, 23086–23102.
- Bartel, D.P., Chen, C.-Z., 2004. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. *Nat. Rev. Genet.* 5, 396–400.
- Benetti, R., Gonzalo, S., Jacio, I., Muñoz, P., Gonzalez, S., Schoeffner, S., et al., 2008. A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. *Nat. Struct. Mol. Biol.* 15, 268–279.
- Bhaumik, D., Scott, G.K., Schokrpur, S., Patil, C.K., Orjalo, A.V., Rodier, F., et al., 2009. MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. *Aging* 1, 402.
- Blenkiron, C., Goldstein, L.D., Thorne, N.P., Spiteri, I., Chin, S.-F., Dunning, M.J., et al., 2007. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. *Genome Biol.* 8, R214.
- Bommer, G.T., Gerin, I., Feng, Y., Kaczorowski, A.J., Kuick, R., Love, R.E., et al., 2007. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. *Curr. Biol.* 17, 1298–1307.
- Bonauer, A., Carmona, G., Iwasaki, M., Mione, M., Koyanagi, M., Fischer, A., et al., 2009. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. *Science* 324, 1710–1713.
- Breier, G., 2000. Angiogenesis in embryonic development—a review. *Placenta* 21, S11–S15.
- Brekken, R.A., Overholser, J.P., Stastny, V.A., Waltenberger, J., Minna, J.D., Thorpe, P.E., 2000. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. *Cancer Res.* 60, 5117–5124.
- Brooks, C.L., Gu, W., 2009. How does SIRT1 affect metabolism, senescence and cancer? *Nat. Rev. Cancer* 9, 123–128.
- Cai, Y., Yu, X., Hu, S., Yu, J., 2009. A brief review on the mechanisms of miRNA regulation. *Genomics Proteomics Bioinforma.* 7, 147–154.
- Calin, G.A., Dumitru, C.D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., et al., 2002. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proc. Natl. Acad. Sci.* 99, 15524–15529.
- Carmeliet, P., 2005. Angiogenesis in life, disease and medicine. *Nature* 438, 932–936.
- Carmeliet, P., Jain, R.K., 2011. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. *Nat. Rev. Drug Discov.* 10, 417–427.
- Catto, J.W., Alcaraz, A., Bjartell, A.S., De Vere, White, R., Evans, C.P., Fussell, S., et al., 2011. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. *Eur. Urol.* 59, 671–681.
- Cha, Y.H., Kim, N.H., Park, C., Lee, I., Kim, H.S., Yook, J.I., 2012. MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. *Cell Cycle* 11, 1273–1281.
- Chang, T.-C., Wentzel, E.A., Kent, O.A., Ramchandran, K., Mullendore, M., Lee, K.H., et al., 2007. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. *Mol. Cell* 26, 745–752.
- Chen, F., Hu, S.J., 2012. Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review. *J. Biochem. Mol. Toxicol.* 26, 79–86.
- Chen, J.J., Lin, Y.-C., Yao, P.-L., Yuan, A., Chen, H.-Y., Shun, C.-T., et al., 2005. Tumor-associated macrophages: the double-edged sword in cancer progression. *J. Clin. Oncol.* 23, 953–964.
- Chen, L.T., Xu, S.D., Xu, H., Zhang, J.F., Ning, J.F., Wang, S.F., 2012. MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumor angiogenesis. *Med. Oncol.* 29, 1673–1680.
- Chim, C., Wong, K., Qi, Y., Loong, F., Lam, W., Wong, L., et al., 2010. Epigenetic inactivation of the miR-34a in hematological malignancies. *Carcinogenesis* 31, 745–750.
- Chiose, S., Jelezcova, E., Chandran, U., Luo, J., Mantha, G., Sobol, R.W., et al., 2007. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. *Cancer Res.* 67, 2345–2350.

- Cho, W., 2010. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. *Int. J. Biochem. Cell Biol.* 42, 1273–1281.
- Choi, Y.J., Lin, C.-P., Ho, J.J., He, X., Okada, N., Bu, P., et al., 2011. miR-34 miRNAs provide a barrier for somatic cell reprogramming. *Nat. Cell Biol.* 13, 1353–1360.
- Christoffersen, N.R., Shalgi, R., Frankel, L., Leucci, E., Lees, M., Klausen, M., et al., 2010. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. *Cell Death Differ.* 17, 236–245.
- Concepcion, C.P., Han, Y.-C., Mu, P., Bonetti, C., Yao, E., D'andrea, A., et al., 2012. Intact p53-dependent responses in miR-34-deficient mice. *PLoS Genet.* 8, e1002797.
- Corney, D.C., Hwang, C.-I., Matoso, A., Vogt, M., Flesken-Nikitin, A., Godwin, A.K., et al., 2010. Frequent downregulation of miR-34 family in human ovarian cancers. *Clin. Cancer Res.* 16, 1119–1128.
- de Antonellis, P., Medaglia, C., Cusanelli, E., Andolfo, I., Liguori, L., De Vita, G., et al., 2011. MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. *PLoS One* 6, e24584.
- Doebele, C., Bonauer, A., Fischer, A., Scholz, A., Reiss, Y., Urbich, C., et al., 2010. Members of the microRNA-17–92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. *Blood* 115, 4944–4950.
- Dorsett, Y., McBride, K.M., Jankovic, M., Gazumyan, A., Thai, T.-H., Robbani, D.F., et al., 2008. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated myc-Igh translocation. *Immunity* 28, 630–638.
- Ebrahimi, F., Gopalan, V., Smith, R.A., Lam, A.K., 2014. miR-126 in human cancers: clinical roles and current perspectives. *Exp. Mol. Pathol.* 96, 98–107.
- Ferrara, N., 2002. VEGF and the quest for tumour angiogenesis factors. *Nat. Rev. Cancer* 2, 795–803.
- Ferrara, N., Kerbel, R.S., 2005. Angiogenesis as a therapeutic target. *Nature* 438, 967–974.
- Ferrara, N., Gerber, H.-P., LeCouter, J., 2003. The biology of VEGF and its receptors. *Nat. Med.* 9, 669–676.
- Ferrara, N., Hillan, K.J., Gerber, H.-P., Novotny, W., 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. *Nat. Rev. Drug Discov.* 3, 391–400.
- Flamme, I., Fröhlich, T., Risau, W., 1997. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. *J. Cell. Physiol.* 173, 206–210.
- Fleissner, F., Jazbutyte, V., Fiedler, J., Gupta, S.K., Yin, X., Xu, Q., et al., 2010. Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. *Circ. Res.* 107, 138–143.
- Fujita, Y., Kojima, K., Hamada, N., Ohhashi, R., Akao, Y., Nozawa, Y., et al., 2008. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. *Biochem. Biophys. Res. Commun.* 377, 114–119.
- Ge, Y., Chen, J., 2011. MicroRNAs in skeletal myogenesis. *Cell Cycle* 10, 441–448.
- Ghosh, G., Subramanian, I.V., Adhikari, N., Zhang, X., Joshi, H.P., Basi, D., et al., 2010. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF- α isoforms and promotes angiogenesis. *J. Clin. Invest.* 120, 4141–4154.
- Gopalan, V., Pillai, S., Ebrahimi, F., Salajegheh, A., Lam, T.C., Le, T.K., Langsford, N., Ho, Y.H., Smith, R.A., Lam, A.K., 2014. Regulation of microRNA-1288 in colorectal cancer: altered expression and its clinicopathological significance. *Mol. Carcinog.* 53 (Suppl. 1), E36–E44.
- Hafner, M., Landthaler, M., Burger, L., Khorshid, M., Hausser, J., Berninger, P., et al., 2010. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. *Cell* 141, 129–141.
- Harhaj, N.S., Felinski, E.A., Wolpert, E.B., Sundstrom, J.M., Gardner, T.W., Antonetti, D.A., 2006. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. *Invest. Ophthalmol. Vis. Sci.* 47, 5106–5115.
- Hayashita, Y., Osada, H., Tatematsu, Y., Yamada, H., Yanagisawa, K., Tomida, S., et al., 2005. A polycistronic microRNA cluster, miR-17–92, is overexpressed in human lung cancers and enhances cell proliferation. *Cancer Res.* 65, 9628–9632.
- Hellstrom, M., Lindahl, P., Abramson, A., Betsholtz, C., 1999. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. *Development* 126, 3047–3055.
- Hermeking, H., 2010. The miR-34 family in cancer and apoptosis. *Cell Death Differ.* 17, 193–199.
- Houbaviy, H.B., Murray, M.F., Sharp, P.A., 2003. Embryonic stem cell-specific microRNAs. *Dev. Cell* 5, 351–358.
- Hu, Z., Chen, X., Zhao, Y., Tian, T., Jin, G., Shu, Y., et al., 2010. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. *J. Clin. Oncol.* 28, 1721–1726.
- Hu, Q., Jiang, Q., Jin, X., Shen, J., Wang, K., Li, Y., et al., 2013. Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. *Biomaterials* 34, 2265–2276.
- Huang, Y., Shen, X.J., Zou, Q., Wang, S.P., Tang, S.M., Zhang, G.Z., 2011. Biological functions of microRNAs: a review. *J. Physiol. Biochem.* 67, 129–139.
- Inui, M., Martello, G., Piccolo, S., 2010. MicroRNA control of signal transduction. *Nat. Rev. Mol. Cell Biol.* 11, 252–263.
- Irani, S., Salajegheh, A., Gopalan, V., Smith, R.A., Lam, A.K., 2014a. Expression profile of endothelin 1 and its receptor endothelin receptor A in papillary thyroid carcinoma and their correlations with clinicopathologic characteristics. *Ann. Diagn. Pathol.* 18, 43–48.
- Irani, S., Salajegheh, A., Smith, R.A., Lam, A.K., 2014b. A review of the profile of endothelin axis in cancer and its management. *Crit. Rev. Oncol. Hematol.* 89, 314–321.
- Ito, T., Yagi, S., Yamakuchi, M., 2010. MicroRNA-34a regulation of endothelial senescence. *Biochem. Biophys. Res. Commun.* 398, 735–740.
- Javeri, A., Ghaffarpour, M., Taha, M.F., Houshmand, M., 2013. Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis. *Med. Oncol.* 30, 1–10.

- Ji, Q., Hao, X., Meng, Y., Zhang, M., DeSano, J., Fan, D., et al., 2008. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. *BMC Cancer* 8, 266.
- Ji, Q., Hao, X., Zhang, M., Tang, W., Yang, M., Li, L., et al., 2009. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. *PLoS One* 4, e6816.
- Karube, Y., Tanaka, H., Osada, H., Tomida, S., Tatematsu, Y., Yanagisawa, K., et al., 2005. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. *Cancer Sci.* 96, 111–115.
- Kasinski, A.L., Slack, F.J., 2011. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. *Nat. Rev. Cancer* 11, 849–864.
- Kato, M., Paranjape, T., Ullrich, R., Nallur, S., Gillespie, E., Keane, K., et al., 2009. The miR-34 microRNA is required for the DNA damage response in vivo in *C. elegans* and in vitro in human breast cancer cells. *Oncogene* 28, 2419–2424.
- Katoh, M., 2013. Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). *Int. J. Mol. Med.* 32, 763–767.
- Koch, A.E., Polverini, P.J., Kunkel, S.L., Harlow, L.A., DiPietro, L.A., Elnor, V.M., et al., 1992. Interleukin-8 as a macrophage-derived mediator of angiogenesis. *Science* 258, 1798–1801.
- Kojima, K., Fujita, Y., Nozawa, Y., Deguchi, T., Ito, M., 2010. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. *Prostate* 70, 1501–1512.
- Kong, D., Heath, E., Chen, W., Cher, M., Powell, I., Heilbrun, L., et al., 2012. Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. *Am. J. Transl. Res.* 4, 14.
- Kong, W., He, L., Richards, E., Challa, S., Xu, C., Permut-Wey, J., et al., 2013. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. *Oncogene*.
- Kopetz, S., Hoff, P.M., Morris, J.S., Wolff, R.A., Eng, C., Glover, K.Y., et al., 2010. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. *J. Clin. Oncol.* 28, 453–459.
- Kota, J., Chivukula, R.R., O'Donnell, K.A., Wentzel, E.A., Montgomery, C.L., Hwang, H.-W., et al., 2009. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. *Cell* 137, 1005–1017.
- Koufaris, C., Wright, J., Currie, R.A., Gooderham, N.J., 2012. Hepatic microRNA profiles offer predictive and mechanistic insights after exposure to genotoxic and epigenetic hepatocarcinogens. *Toxicol. Sci.* 128, 532–543.
- Krol, J., Loedige, I., Filipowicz, W., 2010. The widespread regulation of microRNA biogenesis, function and decay. *Nat. Rev. Genet.* 11, 597–610.
- Kubo, T., Toyooka, S., Tsukuda, K., Sakaguchi, M., Fukazawa, T., Soh, J., et al., 2011. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. *Clin. Cancer Res.* 17, 4965–4974.
- Kumar, M.S., Erkeland, S.J., Pester, R.E., Chen, C.Y., Ebert, M.S., Sharp, P.A., et al., 2008. Suppression of non-small cell lung tumor development by the let-7 microRNA family. *Proc. Natl. Acad. Sci.* 105, 3903–3908.
- Kumar, B., Yadav, A., Lang, J., Teknos, T.N., Kumar, P., 2012. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. *PLoS One* 7, e37601.
- Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., Tuschl, T., 2002. Identification of tissue-specific microRNAs from mouse. *Curr. Biol.* 12, 735–739.
- Lal, A., Thomas, M.P., Altschuler, G., Navarro, F., O'Day, E., Li, X.L., et al., 2011. Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. *PLoS Genet.* 7, e1002363.
- Lau, N.C., Lim, L.P., Weinstein, E.G., Bartel, D.P., 2001. An abundant class of tiny RNAs with probable regulatory roles in *Caenorhabditis elegans*. *Science* 294, 858–862.
- Lee, R.C., Ambros, V., 2001. An extensive class of small RNAs in *Caenorhabditis elegans*. *Science* 294, 862–864.
- Lehmann, U., Hasemeier, B., Christgen, M., Müller, M., Römermann, D., Länger, F., et al., 2008. Epigenetic inactivation of microRNA gene hsa-miR-9-1 in human breast cancer. *J. Pathol.* 214, 17–24.
- Li, N., Fu, H., Tie, Y., Hu, Z., Kong, W., Wu, Y., et al., 2009. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. *Cancer Lett.* 275, 44–53.
- Li, Q., Bian, S., Hong, J., Kawase-Koga, Y., Zhu, E., Zheng, Y., et al., 2011. Timing specific requirement of microRNA function is essential for embryonic and postnatal hippocampal development. *PLoS One* 6, e26000.
- Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., et al., 2011a. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. *Nat. Med.* 17, 211–215.
- Liu, L.-Z., Li, C., Chen, Q., Jing, Y., Carpenter, R., Jiang, Y., et al., 2011b. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1 α expression. *PLoS One* 6, e19139.
- Liu, N., Landreh, M., Cao, K., Abe, M., Hendriks, G.-J., Kennerdell, J.R., et al., 2012. The microRNA miR-34 modulates ageing and neurodegeneration in *Drosophila*. *Nature* 482, 519–523.
- Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Korner, H., et al., 2008. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. *Cell Cycle* 7, 2591–2600.
- Loughna, S., Sato, T.N., 2001. Angiopoietin and Tie signaling pathways in vascular development. *Matrix Biol.* 20, 319–325.
- Ma, J., Chen, C.-S., Blute, T., Waxman, D.J., 2011. Antiangiogenesis enhances intratumoral drug retention. *Cancer Res.* 71, 2675–2685.
- Manley, P.W., Bold, G., Brügger, J., Fendrich, G., Furet, P., Mestan, J., et al., 2004. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. *Biochim. Biophys. Acta Protein Proteomics* 1697, 17–27.
- Mazar, J., Khaitan, D., DeBlasio, D., Zhong, C., Govindarajan, S.S., Kopanathi, S., et al., 2011. Epigenetic regulation of microRNA genes and the role of miR-34b in cell invasion and motility in human melanoma. *PLoS One* 6, e24922.
- Miles, K., 1999. Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. *Eur. J. Radiol.* 30, 198–205.
- Mudduluru, G., Ceppi, P., Kumarswamy, R., Scagliotti, G., Papotti, M., Allgayer, H., 2011. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. *Oncogene* 30, 2888–2899.
- Muralidhar, B., Goldstein, L., Ng, G., Winder, D., Palmer, R., Gooding, E., et al., 2007. Global microRNA profiles in cervical squamous cell carcinoma depend on Droscha expression levels. *J. Pathol.* 212, 368–377.
- Nakashima, T., Jinnin, M., Etoh, T., Fukushima, S., Masuguchi, S., Maruo, K., et al., 2010. Down-regulation of mir-424 contributes to the abnormal angiogenesis via MEK1 and cyclin E1 in senile hemangioma: its implications to therapy. *PLoS One* 5, e14334.
- Nalls, D., Tang, S.-N., Rodova, M., Srivastava, R.K., Shankar, S., 2011. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. *PLoS One* 6, e24099.
- Nicoli, S., Knyphausen, C.-P., Zhu, L.J., Lakshmanan, A., Lawson, N.D., 2012. miR-221 is required for endothelial tip cell behaviors during vascular development. *Dev. Cell* 22, 418–429.
- Otrock, Z.K., Mahfouz, R.A., Makarem, J.A., Shamseddine, A.I., 2007. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. *Blood Cell Mol. Dis.* 39, 212–220.
- Perren, T.J., Swart, A.M., Pfisterer, J., Ledermann, J.A., Pujade-Lauraine, E., Kristensen, G., et al., 2011. A phase 3 trial of bevacizumab in ovarian cancer. *N. Engl. J. Med.* 365, 2484–2496.
- Presta, M., Dell'Era, P., Mitola, S., Moroni, E., Ronca, R., Rusnati, M., 2005. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. *Cytokine Growth Factor Rev.* 16, 159–178.
- Rebustini, I.T., Hayashi, T., Reynolds, A.D., Dillard, M.L., Carpenter, E.M., Hoffman, M.P., 2012. miR-200c regulates FGFR-dependent epithelial proliferation via Vldlr during submandibular gland branching morphogenesis. *Development* 139, 191–202.
- Reis, S.T., Leite, K.R.M., Piovesan, L.F., Pontes-Junior, J., Viana, N.I., Abe, D.K., et al., 2012. Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer. *BMC Urol.* 12, 18.
- Rinaldi, A., Poretti, G., Kwee, I., Zucca, E., Catapano, C.V., Tibiletti, M.G., et al., 2007. Concomitant MYC and microRNA cluster miR-17–92 (C13orf25) amplification in human mantle cell lymphoma. *Leuk. Lymphoma* 48, 410–412.
- Roy, S., Levi, E., Majumdar, A., Sarkar, F.H., 2012. Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. *J. Hematol. Oncol.* 5, 58.
- Salajegheh, A., Smith, R.A., Kasem, K., Gopalan, V., Nassiri, M.R., William, R., Lam, A.K., 2011. Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes. *Eur. J. Surg. Oncol.* 37, 93–99.
- Salajegheh, A., Pakneshan, S., Rahman, A., Dolan-Evans, E., Zhang, S., Kwong, E., Gopalan, V., 2010. Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma. *Hum. Pathol.* 44, 2204–2212.
- Savi, F., Forno, I., Favarsani, A., Luciani, A., Caldiera, S., Gatti, S., et al., 2014. miR-296/Scribble axis is deregulated in human breast cancer and miR-296 restoration reduces tumour growth in vivo. *Clin. Sci.* 127, 233–242.
- Sayed, D., Abdellatif, M., 2011. MicroRNAs in development and disease. *Physiol. Rev.* 91, 827–887.
- Segura, M.F., Hanniford, D., Menendez, S., Reavie, L., Zou, X., Alvarez-Diaz, S., et al., 2009. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. *Proc. Natl. Acad. Sci.* 106, 1814–1819.
- Semenza, G.L., 2000. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. *Crit. Rev. Biochem. Mol. Biol.* 35, 71–103.
- Semenza, G.L., 2002. HIF-1 and tumor progression: pathophysiology and therapeutics. *Trends Mol. Med.* 8, S62–S67.
- Sevignani, C., Calin, G.A., Nnadi, S.C., Shimizu, M., Davuluri, R.V., Hyslop, T., et al., 2007. MicroRNA genes are frequently located near mouse cancer susceptibility loci. *Proc. Natl. Acad. Sci.* 104, 8017–8022.
- Shojaei, F., 2012. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. *Cancer Lett.* 320, 130–137.
- Siemens, H., Jackstadt, R., Hunte, S., Kaller, M., Menssen, A., Gotz, U., et al., 2011. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. *Cell Cycle* 10, 4256–4271.
- Siemens, H., Neumann, J., Jackstadt, R., Mansmann, U., Horst, D., Kirchner, T., et al., 2013. Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and β -catenin predicts distant metastasis of colon cancer. *Clin. Cancer Res.* 19, 710–720.
- Siomi, H., Siomi, M.C., 2010. Posttranscriptional regulation of microRNA biogenesis in animals. *Mol. Cell* 38, 323–332.
- Sitohy, B., Nagy, J.A., Dvorak, H.F., 2012. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. *Cancer Res.* 72, 1909–1914.
- Suárez, Y., Fernández-Hernando, C., Yu, J., Gerber, S.A., Harrison, K.D., Pober, J.S., et al., 2012. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. *Circulation* 125, 1176–1184.
- Sun, C.Y., She, X.M., Qin, Y., Chu, Z.B., Chen, L., Ai, L.S., et al., 2013. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. *Carcinogenesis* 34, 426–435.
- Szulwach, K.E., Li, X., Smrt, R.D., Li, Y., Luo, Y., Lin, L., et al., 2010. Cross talk between microRNA and epigenetic regulation in adult neurogenesis. *J. Cell Biol.* 189, 127–141.
- Tagawa, H., Karube, K., Tsuzuki, S., Ohshima, K., Seto, M., 2007. Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development. *Cancer Sci.* 98, 1482–1490.

- Tazawa, H., Tsuchiya, N., Izumiya, M., Nakagama, H., 2007. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. *Proc. Natl. Acad. Sci.* 104, 15472–15477.
- Toyota, M., Suzuki, H., Sasaki, Y., Maruyama, R., Imai, K., Shinomura, Y., et al., 2008. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. *Cancer Res.* 68, 4123–4132.
- Tsao, M.-S., Sakurada, A., Cutz, J.-C., Zhu, C.-Q., Kamel-Reid, S., Squire, J., et al., 2005. Erlotinib in lung cancer—molecular and clinical predictors of outcome. *N. Engl. J. Med.* 353, 133–144.
- Vaira, V., Favarsani, A., Dohi, T., Montorsi, M., Augello, C., Gatti, S., et al., 2012. miR-296 regulation of a cell polarity–cell plasticity module controls tumor progression. *Oncogene* 31, 27–38.
- van Kouwenhove, M., Kedde, M., Agami, R., 2011. MicroRNA regulation by RNA-binding proteins and its implications for cancer. *Nat. Rev. Cancer* 11, 644–656.
- Vogt, M., Munding, J., Grüner, M., Liffers, S.-T., Verdoodt, B., Hauk, J., et al., 2011. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. *Virchows Arch.* 458, 313–322.
- Volpe, M., Nielsen, H., Mujahid, S., 2012. Opposing roles of Mir-221 and Mir-130a in neovascularization during lung branching morphogenesis. *Am. J. Respir. Crit. Care Med.* 185, A4978.
- Wan, G., Mathur, R., Hu, X., Zhang, X., Lu, X., 2011. miRNA response to DNA damage. *Trends Biochem. Sci.* 36, 478–484.
- Wang, S., Aurora, A.B., Johnson, B.A., Qi, X., McAnally, J., Hill, J.A., et al., 2008. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. *Dev. Cell* 15, 261–271.
- Wang, X., Huang, W., Liu, G., Cai, W., Millard, R.W., Wang, Y., et al., 2014. Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells. *J. Mol. Cell. Cardiol.*
- Watahiki, A., Wang, Y., Morris, J., Dennis, K., O'Dwyer, H.M., Gleave, M., et al., 2011. MicroRNAs associated with metastatic prostate cancer. *PLoS One* 6, e24950.
- Waugh, D.J., Wilson, C., 2008. The interleukin-8 pathway in cancer. *Clin. Cancer Res.* 14, 6735–6741.
- Weekes, J., Ho, Y.H., Sebesan, S., Ong, K., Lam, A.K., 2010. Irinotecan and colorectal cancer: the role of p53, VEGF-C and alpha-B-crystallin expression. *Int. J. Color. Dis.* 25, 907.
- Weeraratne, S.D., Amani, V., Neiss, A., Teider, N., Scott, D.K., Pomeroy, S.L., et al., 2011. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. *Neuro-Oncology* 13, 165–175.
- Welch, S.A., Moore, M.J., 2007. Erlotinib: Success of a Molecularly Targeted Agent for the Treatment of Advanced Pancreatic Cancer.
- Welter, J., Loges, S., Dimmeler, S., Carmeliet, P., 2013. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. *J. Clin. Invest.* 123, 3190–3200.
- Wiggins, J.F., Ruffino, L., Kelnar, K., Omotola, M., Patrawala, L., Brown, D., et al., 2010. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. *Cancer Res.* 70, 5923–5930.
- Winter, J., Jung, S., Keller, S., Gregory, R.I., Diederichs, S., 2009. Many roads to maturity: microRNA biogenesis pathways and their regulation. *Nat. Cell Biol.* 11, 228–234.
- Wu, Y.-Y., Chen, Y.-L., Jao, Y.-C., Hsieh, I.-S., Chang, K.-C., Hong, T.-M., 2014. miR-320 regulates tumor angiogenesis driven by vascular endothelial cells in oral cancer by silencing neuropilin 1. *Angiogenesis* 17, 247–260.
- Yamakuchi, M., Lowenstein, C.J., 2009. MiR-34, SIRT1 and p53. *Cell Cycle* 8, 712–715.
- Yamakuchi, M., Ferlito, M., Lowenstein, C.J., 2008. miR-34a repression of SIRT1 regulates apoptosis. *Proc. Natl. Acad. Sci.* 105, 13421–13426.
- Yan, L.X., Wu, Q.N., Zhang, Y., Li, Y.Y., Liao, D.Z., Hou, J.H., et al., 2011. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. *Breast Cancer Res.* 13, R2.
- Yang, W.J., Yang, D.D., Na, S., Sandusky, G.E., Zhang, Q., Zhao, G., 2005. Dicer is required for embryonic angiogenesis during mouse development. *J. Biol. Chem.* 280, 9330–9335.
- Yu, X.M., Lo, C.Y., Lam, A.K., Lang, B.H., Leung, P., Luk, J.M., 2008a. The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma. *Surgery* 144, 934–940.
- Yu, X.M., Lo, C.Y., Lam, A.K., Leung, P., Luk, J.M., 2008b. Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. *Ann. Surg.* 247, 483–489.
- Yu, F., Jiao, Y., Zhu, Y., Wang, Y., Zhu, J., Cui, X., et al., 2012. MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial–mesenchymal transition in breast tumor-initiating cells. *J. Biol. Chem.* 287, 465–473.
- Zhang, Q., Kandic, I., Kutryk, M.J., 2011. Dysregulation of angiogenesis-related microRNAs in endothelial progenitor cells from patients with coronary artery disease. *Biochem. Biophys. Res. Commun.* 405, 42–46.
- Zhang, S., Liu, L., Wang, R., Tuo, H., Guo, Y., Yi, L., et al., 2013. MicroRNA-217 promotes angiogenesis of human cytomegalovirus-infected endothelial cells through downregulation of SIRT1 and FOXO3A. *PLoS One* 8, e83620.
- Zhao, T., Li, J., Chen, A.F., 2010. MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenesis via suppressing silent information regulator 1. *Am. J. Physiol. Endocrinol. Metab.* 299, E110.
- Zhuang, G., Wu, X., Jiang, Z., Kasman, I., Yao, J., Guan, Y., et al., 2012. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK–STAT pathway. *EMBO J.* 31, 3513–3523.